Top Biomedical & Pharma Stocks
Biomedical and pharmaceutical stocks combine durable cash flows from approved blockbuster drugs with high-variance pipeline optionality. Phase 3 trial readouts, FDA approval decisions, and patent cliffs create regular binary events that can move individual names 20–50% in a single session. The companies listed here combine commercial-stage revenue with deep late-stage pipelines across the most important therapeutic areas.
Lilly's Mounjaro and Zepbound dominate the GLP-1 obesity and diabetes market. Its Phase 3 pipeline spans cardiovascular, renal, Alzheimer's, and oral GLP-1, each representing a potential multi-billion revenue catalyst over the next three years.
Fast revenue growth (+56% YoY).
AbbVie's Skyrizi and Rinvoq are replacing Humira's revenue as it loses exclusivity — a remarkably successful patent cliff navigation. Its oncology portfolio (Imbruvica, Venclexta) provides additional growth. Pipeline depth across immunology and neuroscience supports premium valuation.
Moderate upside to target (+11%) and attractive valuation (14x forward P/E).
J&J's pharmaceutical segment (Janssen) spans oncology, immunology, and neuroscience, led by Darzalex (blood cancer) and Tremfya. Its MedTech segment provides a durable revenue floor while innovative medicine drives growth.
Limited near-term upside (+5% to target).
Pfizer is navigating the post-COVID revenue reset by deploying its mRNA platform into oncology and influenza vaccines. Its Seagen acquisition adds a deep ADC pipeline. At sub-10x forward P/E the stock prices in significant skepticism — meaningful upside if even 2–3 pipeline assets succeed.
Moderate upside to target (+11%) and the most attractive valuation in the group (9x forward P/E).
Regeneron's VelociSuite antibody technology platform enables rapid drug discovery. Dupixent (atopic dermatitis, asthma, COPD) is one of the fastest-growing drugs in pharma history. Its oncology pipeline includes Libtayo and multiple ADC candidates in late-stage trials.
The highest analyst upside in the group (+36% to target) and attractive valuation (11x forward P/E).
Amgen's MariTide is a Phase 3 obesity drug candidate that could be differentiated from GLP-1s. Its established biologics franchise (Enbrel, Otezla, Repatha) generates the cash flow to fund the pipeline. CareDx and Horizon Therapeutics acquisitions add rare disease exposure.
Strong price momentum (+17% over 1Y) and attractive valuation (15x forward P/E), though analyst targets below the current price (-1%).
Gilead's Trodelvy (TROP-2 ADC) and Yescarta/Tecartus (CAR-T) represent a genuine oncology transition from its HIV/antiviral franchise. Lenacapavir's twice-yearly HIV prevention trial (PURPOSE 1) showed 100% efficacy — a potential blockbuster rerating catalyst.
Solid 1-year momentum (+15%), strong upside potential (+25% to analyst target), and attractive valuation (13x forward P/E).
Keytruda is the world's best-selling oncology drug ($25B+ annually) and is being tested in 1,600+ clinical trials. Merck's pipeline extends Keytruda into earlier cancer stages and ADC combinations, extending its revenue runway well past 2030.
Moderate upside to target (+9%) and attractive valuation (12x forward P/E).
BMS faces LOE headwinds on Revlimid and Opdivo but its new product portfolio (Reblozyl, Camzyos, Sotyktu, Cobenfy) is growing rapidly. Its Opdivo + Yervoy combinations continue to expand into new cancer indications, and Cobenfy (schizophrenia) opens a large new market.
Solid 1-year momentum (+15%), moderate upside to target (+10%), and attractive valuation (9x forward P/E).
Vertex has a monopoly on cystic fibrosis treatment with Trikafta/Kaftrio. Its gene editing partnership with CRISPR Therapeutics produced Casgevy, the first approved CRISPR cure (sickle cell disease). Type 1 diabetes cell therapy and AAT deficiency are additional late-stage pipeline catalysts.
Moderate upside to target (+23%).
- GLP-1 obesity market expands to $150B+ by 2030 with oral formulations, new indications, and emerging market penetration
- Keytruda label expansions and ADC combinations keep oncology drugs growing well past 2028 patent cliffs
- CRISPR/gene therapy approvals (Casgevy, follow-ons) validate a new therapeutic modality worth hundreds of billions
- Aging global demographics structurally expand the addressable patient population for oncology, metabolic disease, and rare disease
- Phase 3 trial failures in high-expectation programs (oral GLP-1, Alzheimer's, major oncology) can erase 20–40% of market cap in a day
- Medicare drug price negotiations under the IRA compress pricing on blockbuster drugs with large patient volumes
- Patent cliffs for Keytruda (2028), Dupixent, and Skyrizi create multi-year revenue replacement challenges
- Compounding pharmacy competition in GLP-1 market if FDA allows continued access to compound alternatives
- Binary Phase 3 trial readout risk — any major failure moves stock 20–50% in a single session
- IRA drug price negotiation impact on high-revenue brands is still being assessed and could compress terminal multiples
- Patent cliff timing risk — Keytruda LOE in 2028 is the single largest overhang in the sector
- Regulatory delays at FDA for NMEs or BLAs can defer expected revenue by 12–24 months
- M&A premiums paid to replenish pipelines (Pfizer/Seagen, AbbVie/ImmunoGen) must be justified by clinical execution
Prefer passive exposure to this theme? These ETFs provide broad coverage without individual stock selection.
Frequently Asked Questions
What makes biomedical and pharma stocks different from other sectors?+
Pharma and biotech stocks have a unique risk/return profile: durable cash flows from approved drugs combined with high-variance pipeline optionality. A single Phase 3 trial success or failure can move a stock 30–50% in one session — far more than most other sectors.
What are the most important catalysts to watch for pharma stocks?+
The five biggest catalysts are: (1) Phase 3 trial readouts, (2) FDA approval decisions (PDUFA dates), (3) major data presentations at ASCO, ASH, ACC, and other medical congresses, (4) patent cliff timing for blockbuster drugs, and (5) drug price negotiation outcomes under the IRA.
How should I size biomedical stocks in a portfolio?+
Given their binary event risk, individual clinical-stage biotech positions are best kept to 1–3% of a portfolio. Large-cap pharma names with diversified portfolios (JNJ, MRK, ABBV) carry lower event risk and can be sized like other large-caps at 3–6%. Always watch the pipeline calendar for upcoming Phase 3 readouts.
Sign in to BriMindInvest to compare any two stocks with live metrics, AI scores, valuation charts, and personalised insights.